Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features is a phase 2, interventional study registered as NCT06449313 by Georgetown University, with a registry enrolment figure of 21 participants, started 2026-08 and due to reach its primary completion in 2027-12. Interventions recorded: Cemiplimab-Rwlc. Conditions listed: Non-small Cell Lung Cancer Stage III. Primary outcome: Pathologic complete response (pCR) rate. Lung eligibility wording from the registry: "Histologically or cytologically confirmed stage 3 Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJCC) that meets one of the below criteria:". Sites: United States. No results are recorded here; the registry entry is the source.